This CME-certified Webcast contains video and downloadable slides from the symposium Transforming Advanced Lung Cancer Into a Chronic Disease: Answering Key Question’s, a prIME Oncology educational activity that was held on Monday, September 7, 2015, in Denver, in conjunction with the 16th World Conference on Lung Cancer.
Is non-small cell lung cancer (NSCLC) becoming a chronic disease?
Paul A. Bunn, Jr, MD
What are the best strategies to overcome acquired tyrosine kinase inhibitor resistance?
Suresh Ramalingam, MD
When should an immunotherapeutic approach be considered in NSCLC management?
Joel Neal, MD, PhD
Paul A. Bunn, Jr, MDUniversity of Colorado Denver
Denver, Colorado, United States
Joel Neal, MD, PhDStanford Comprehensive Cancer Center
Stanford, California, United States
Suresh Ramalingam, MDWinship Cancer Institute
Atlanta, Georgia, United States
This activity is designed to meet the needs of medical oncologists, surgical and radiation oncologists, pulmonologists, pathologists, and other healthcare professionals involved in the treatment of patients with NSCLC.
After successful completion of this educational activity, participants should be able to:
- Discuss the mechanisms of acquired resistance to tyrosine kinase inhibitors (TKIs) in NSCLC
- Explain emerging strategies to overcome resistance to TKIs in the treatment of NSCLC
- Discuss emerging data on treatment agents and immunotherapeutic approaches for NSCLC, including oncogenic signaling inhibitors
This activity is provided by prIME Oncology.
prIME Oncology is accredited by the Accreditation Council for Continuing Medical Education (ACCME®) to provide continuing medical education for physicians.
prIME Oncology designates this enduring activity for a maximum of 1 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
This educational activity is supported by a grant from AstraZeneca.
October 30, 2015
October 30, 2016